Drugs / Rupatadine
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06708520 | Nov 2022 → Jul 2025 overdue | impaired renal function disease | Noucor Health S.A. | Recruiting | No outcome recorded |
| Phase 1 | NCT06736340 | Nov 2022 → Apr 2025 | — | Noucor Health S.A. | Completed | No outcome recorded |
| Phase 1 | NCT05356143 | Dec 2021 → Jan 2022 | — | J. Uriach and Company | Completed | No outcome recorded |
| Phase 1 | NCT00199225 | Feb → Jul 2005 | — | J. Uriach and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01605487 | Jun 2012 → Sep 2013 | cold urticaria | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00199238 | Oct 2002 → Nov 2003 | chronic idiopathic urticaria | J. Uriach and Company | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00199251 | Apr 2004 → Jun 2005 | urticaria | J. Uriach and Company | Terminated | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT04601324 | Dec 2020 → Jun 2021 | allergic rhinitis | St. Paul's Sinus Centre | Withdrawn | No outcome recorded |
| Phase 4 | NCT00162786 | May → Nov 2005 | — | J. Uriach and Company | Terminated | No outcome recorded |
| Phase 4 | NCT00258141 | — | allergic disease | J. Uriach and Company | Unknown | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT07064707 Comparator | Jul 2025 → Jul 2026 overdue | ulcerative colitis | Alexandria University | Recruiting | No outcome recorded |
| Phase 3 | NCT07711262 Comparator | Aug 2026 → Oct 2027 expected | seasonal allergic rhinitis | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT03770923 Comparator | Oct 2018 → Oct 2026 expected | rheumatoid arthritis | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT02358265 Comparator | Dec 2014 → Nov 2017 | chronic urticaria | Charite University, Berlin, Germany | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rupatadine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06736340 ↗ |
| Known as | RUP | “Investigating the efficacy and safety of rupatadine (RUP) versus montelukast (MON) as adjuvant therapy for patients with rheumatoid arthritis (RA).” PMID 34218304 ↗ Jul 2021 |
| Known as | Rupatadina | ChEMBL registry synonym — accepted as the source's own label CHEMBL91397 ↗ |
| Known as | Rupatadine Fumarate | “Drug: Rupatadine Fumarate” NCT00199238 ↗ |
| Known as | UR-12592 | ChEMBL registry synonym — accepted as the source's own label CHEMBL91397 ↗ |
| Action | Inhibit | “Oral rupatadine is a potent antihistamine and platelet activating factor (PAF) antagonist” NCT04601324 ↗2“Platelet activating factor receptor antagonist” CHEMBL91397 ↗ “Histamine H1 receptor antagonist” CHEMBL91397 ↗ |
| Modality | Small molecule | — CHEMBL91397 ↗ |
| Route | Oral | “oral dose of 1 tablet/day” NCT00199238 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL91397 ↗ |
| Target | PTAFR | “Platelet activating factor receptor antagonist” CHEMBL91397 ↗ |